Homocysteine levels, paraoxonase 1 (PON1) activity, and cardiovascular risk

JAMA

Volumn 300, Issue 2, 2008, Pages 168-169

  Vos, Eddie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE;

AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; ENZYME ACTIVITY; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 47049118473     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.2.168     Document Type: Letter

References (5)

1. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299(11):1265-1276.
2. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. Biol Chem. 2000;275(6):3957-3962.
3. Domagała TB, Łacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-le-grand). 2006;52(5):4-10.
4. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-1577.
5. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA. 2005;293(9):1082-1088.